Drug intelligence / Profile preview

cytarabine + etoposide + pirarubicin

Development stage: Unknown
Lead developer: Japanese Childhood AML Cooperative Study Group
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of cytarabine, etoposide, and pirarubicin. This regimen was specifically designed as a less intensive chemotherapeutic approach for patients with Down syndrome and acute myeloid leukemia (AML). Studies by the Japanese Childhood AML Cooperative Study Group have shown excellent outcomes with this combination, achieving a 97.2% complete remission rate and an estimated 4-year event-free survival rate of 83% in AML-DS patients.

Targets

TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on cytarabine + etoposide + pirarubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cytarabine + etoposide + pirarubicin.

Explore the full profile